Transitions of care between jail-based medications for opioid use disorder and ongoing treatment in the community: A retrospective cohort study DOI Creative Commons
Noa Krawczyk, Sungwoo Lim, Teena Cherian

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: Nov. 11, 2023

Abstract Background and Aims Offering medications for opioid use disorder (MOUD) in carceral settings can significantly reduce overdose risk. However, it is unknown whether to what extent individuals U.S. jail continue MOUD once they leave incarceration, factors influence treatment continuity. Design Retrospective cohort study of linked jail-based electronic health records community OUD claims. Setting New York City Jail Participants Incarcerations with discharged from the between May 1, 2011 December 31, 2017 Comparators Receiving vs. not receiving (methadone or buprenorphine) at time release Measurements We measured continuity community-based within one month release, among those without during jail. tested effect modification based on receipt prior incarceration assessed associated discontinuation upon re-entry. Findings Of 28,298 eligible incarcerations, 52.8% received release. 30% incarcerations had a claim 30 days compared 7% (Risk Ratio: 2.62 (2.44-2.82)). Most (69%) claims who in-jail continued community, only 9% MOUD. Among were younger, Non-Hispanic Black no history less likely following Conclusions maintenance strongly Still, findings highlight gap upon-reentry, especially initiate In wake worsening deaths troubling disparities, improving continuty evidence-based care this population must be an urgent policy priority.

Language: Английский

Emergency Clinician Buprenorphine Initiation, Subsequent Prescriptions, and Continuous Prescriptions DOI

Annette M. Dekker,

David L. Schriger,

Andrew A. Herring

et al.

JAMA, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 19, 2025

Importance Rates of opioid use disorder (OUD) and associated mortality in the US remain high. Treatment OUD with buprenorphine reduces morbidity mortality. There have been national efforts to expand initiation emergency department (ED), where many patients low treatment access seek medical care. Adoption trends clinician prescribing are unknown. Objective To describe for OUD, subsequent prescriptions, changes over time California. Design, Setting, Participants Observational retrospective study prescriptions California Controlled Substance Utilization Review Evaluation System (CURES) database from January 1, 2017, December 31, 2022. Any patient aged 18 79 years a zip code who filled prescription CURES their prescribers were eligible inclusion. Exposure Buprenorphine by an clinician. Main Outcomes Measures included (1) number prescribed buprenorphine; (2) clinicians (3) characteristics prescriptions; (4) percentage linkage second continuous also reported as continuation ratio; (5) days prior prescriptions. Results In this observational study, 345 024 received 3.8 million 21 099 2017 The mean age at first was 37 years; 8187 (67%) male. Emergency increased 2% (n = 78) 16% 1789) 2022, respectively ( P < .001). 0.1% 53) 5% 4493) all ratio receive within 40 ED 2.8 (10 823/3916). start 180 or more 18.3 823/593) 9.1 1 year (5989/655 [2017-2021 data]). Conclusions Relevance These findings suggest increasing approximately 9 going on year.

Language: Английский

Citations

1
Hepatitis C Treatment in Kentucky Medicaid Recipients with Concurrent Opioid Use Disorder: A Cross-Sectional Study DOI
Olivia K. Sugarman, Brendan Saloner, Samantha J. Harris

et al.

Journal of General Internal Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 21, 2025

Language: Английский

Citations

0
Opioid Treatment Programs and Risks for COVID-19 Infections, Emergency Visits, and Hospitalizations DOI
Ryan Cook,

Kendra L. Blalock,

Sanae El Ibrahimi

et al.

Journal of General Internal Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 25, 2025

Language: Английский

Citations

0
Tele-Buprenorphine Initiations for Opioid Use Disorder Without In-Person Relationships DOI Creative Commons
Emma E. McGinty, Y L Ge, Jiani Yu

et al.

JAMA Network Open, Journal Year: 2025, Volume and Issue: 8(3), P. e250001 - e250001

Published: March 3, 2025

This cross-sectional study examines the proportion of individuals with opioid use disorder (OUD) who initiated buprenorphine treatment without in-person visits under a temporary rule allowing tele-initiation controlled substances.

Language: Английский

Citations

0
Drug treatment and support service utilization amidst the COVID-19 pandemic among people who inject drugs in Baltimore, Maryland: An interrupted time-series analysis, 2015–2022 DOI
Eshan U. Patel, Jacqueline E. Rudolph, Kenneth A. Feder

et al.

International Journal of Drug Policy, Journal Year: 2025, Volume and Issue: 138, P. 104746 - 104746

Published: March 3, 2025

Language: Английский

Citations

0
Patient and clinician experiences with the implementation of telemedicine and related adaptations in office-based buprenorphine treatment during the COVID-19 pandemic: a qualitative study DOI Creative Commons
Melissa Davoust, Angela R. Bazzi, Samantha Blakemore

et al.

Addiction Science & Clinical Practice, Journal Year: 2025, Volume and Issue: 20(1)

Published: March 4, 2025

Abstract Background Deaths from opioid overdose have increased dramatically in the past decade. For individuals with use disorder (OUD), agonist medications such as methadone and buprenorphine reduce opioid-related morbidity mortality. Historically, provision of treatment office-based settings has relied on frequent in-person contact, likely influencing patients’ access to retention care. In response COVID-19 pandemic, providers rapidly adapted their care processes, increasingly relying telemedicine visits. To date, relatively few prior studies combined patient clinician perspectives examine implementation related adaptations, particularly safety-net settings. Methods Qualitative methods were used explore experiences an clinic affiliated urban hospital. From this clinic, we conducted semi-structured interviews 25 patients 16 clinicians (including prescribers non-prescribers). We coded all interview data a thematic analysis approach understand how impacted quality engagement care, well preferences for using moving forward. Results Five themes regarding other COVID-19-related adaptations arose perspectives: (1) integration precipitated openness more flexibility practices, (2) concerns telemedicine-related centered around safety accountability, (3) encounters required rapport trust between facilitate open communication, (4) populations experienced unique challenges when telemedicine, terms technology need privacy, (5) there is important role forward, primarily through its hybrid models which integrate both virtual Conclusions Telemedicine within potential improve care; however, our findings emphasize tailored approaches implementing treatment, Overall, study supports maintenance changes policy practice that beyond public health emergency.

Language: Английский

Citations

0
Primary care professionals’ perspectives on tailoring buprenorphine training for rural practice DOI Creative Commons
Cheyenne Fenstemaker, Elizabeth A. Abrams, Benjamin Obringer

et al.

The Journal of Rural Health, Journal Year: 2024, Volume and Issue: 40(4), P. 671 - 680

Published: March 14, 2024

Abstract Purpose Buprenorphine is a highly effective medication for opioid use disorder (OUD) that remains substantially underutilized by primary care professionals (PCPs). This particularly true in rural communities, which have fewer prescribers and significant access disparities. The Drug Enforcement Administration removed the X‐waiver requirement December 2022, yet many clinicians still report barriers to prescribing buprenorphine. In this study, we examined PCPs’ experiences with buprenorphine identify tailored training strategies practice. Methods Physicians, nurse practitioners, physician associates practicing Ohio counties were recruited through contacts at statewide health associations professions programs. Twenty‐three PCPs interviewed about their perspectives on buprenorphine, including history. Findings self‐reported being motivated respond OUD. However, they also reported current efforts failed equip them knowledge resources needed prescribe effectively, urban‐focused often alienated clinicians. Participants suggested tailoring content settings, using trainers, bolstering confidence navigating rural‐specific barriers, such as resource deficits acute fatigue. Conclusion Our study found inadequate meeting needs of PCPs. Tailored improve accessibility acceptability, better support clinical workforce communities disproportionately impacted epidemic.

Language: Английский

Citations

3
Structural and social changes due to the COVID-19 pandemic and their impact on engagement in substance use disorder treatment services: a qualitative study among people with a recent history of injection drug use in Baltimore, Maryland DOI Creative Commons
Eshan U. Patel, Suzanne M. Grieb, Abigail K. Winiker

et al.

Harm Reduction Journal, Journal Year: 2024, Volume and Issue: 21(1)

Published: May 8, 2024

Abstract Background Substance use disorder treatment and recovery support services are critical for achieving maintaining recovery. There limited data on how structural social changes due to the COVID-19 pandemic impacted individual-level experiences with substance treatment-related among community-based samples of people who inject drugs. Methods People a recent history injection drug were enrolled in AIDS Linked IntraVenous Experience study Baltimore, Maryland participated one-time, semi-structured interview between July 2021 February 2022 about their living through (n = 28). An iterative inductive coding process was used identify themes describing affected participants’ services. Results The median age participants 54 years (range 24–73); 10 (36%) female, 16 (57%) non-Hispanic Black, 8 (29%) HIV. We identified several that acted as barriers facilitators engagement medications opioid (MOUD) (e.g., group meetings). New take-home methadone flexibility policies temporarily facilitated MOUD treatment, but other pre-existing rigid practices zero-tolerance) counteracting barriers. Changes illicit market both facilitator barrier treatment. Decreased availability pandemic-related adaptations in-person While telehealth expansion meetings some participants, faced digital technological These service provision also led diminished perceived quality virtual meetings. However, increased accessibility individual providers counselors Sponsors). Conclusions Structural across socioecological levels created new Multilevel interventions needed improve access high-quality

Language: Английский

Citations

3
Transitions of care between jail-based medications for opioid use disorder and ongoing treatment in the community: A retrospective cohort study DOI
Noa Krawczyk, Sungwoo Lim, Teena Cherian

et al.

Drug and Alcohol Dependence, Journal Year: 2024, Volume and Issue: 261, P. 111377 - 111377

Published: June 24, 2024

Language: Английский

Citations

3
Community-Based Medications First for Opioid Use Disorder - Care Utilization and Mortality Outcomes DOI Creative Commons
Caleb J. Banta‐Green, Mandy D. Owens, Jason Williams

et al.

Substance Abuse and Rehabilitation, Journal Year: 2024, Volume and Issue: Volume 15, P. 173 - 183

Published: Sept. 1, 2024

A large treatment gap exists for people who could benefit from medications opioid use disorder (MOUD). People OUD accessing services in harm reduction and community-based organizations often have difficulty engaging MOUD at programs traditional health care settings. We conducted a study to test the impacts of first model six Washington (WA) State communities that provided drop-in access.

Language: Английский

Citations

1